[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE286500T1 - 1,2,3,4-tetrahydroisochinolin-derivate - Google Patents

1,2,3,4-tetrahydroisochinolin-derivate

Info

Publication number
ATE286500T1
ATE286500T1 AT01933685T AT01933685T ATE286500T1 AT E286500 T1 ATE286500 T1 AT E286500T1 AT 01933685 T AT01933685 T AT 01933685T AT 01933685 T AT01933685 T AT 01933685T AT E286500 T1 ATE286500 T1 AT E286500T1
Authority
AT
Austria
Prior art keywords
derivatives
tetrahydroisocinoline
preparation
pharmaceutical compositions
compounds
Prior art date
Application number
AT01933685T
Other languages
German (de)
English (en)
Inventor
Hamed Aissaoui
Michael Cappi
Martine Clozel
Ralf Koberstein
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE286500T1 publication Critical patent/ATE286500T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18Aralkyl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18Aralkyl radicals
    • C07D217/20Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT01933685T 2000-03-14 2001-03-12 1,2,3,4-tetrahydroisochinolin-derivate ATE286500T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0002245 2000-03-14
PCT/EP2001/002733 WO2001068609A1 (en) 2000-03-14 2001-03-12 1,2,3,4-tetrahydroisoquinoline derivatives

Publications (1)

Publication Number Publication Date
ATE286500T1 true ATE286500T1 (de) 2005-01-15

Family

ID=8163870

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01933685T ATE286500T1 (de) 2000-03-14 2001-03-12 1,2,3,4-tetrahydroisochinolin-derivate

Country Status (18)

Country Link
US (1) US6703392B2 (xx)
JP (1) JP4009460B2 (xx)
KR (2) KR100842698B1 (xx)
CN (1) CN100393703C (xx)
AT (1) ATE286500T1 (xx)
AU (2) AU2001260113B2 (xx)
BR (1) BRPI0109200B8 (xx)
CA (1) CA2402431C (xx)
DE (1) DE60108236T2 (xx)
ES (1) ES2234840T3 (xx)
HU (1) HU227811B1 (xx)
IL (2) IL150986A0 (xx)
MX (1) MXPA02008797A (xx)
NO (1) NO324932B1 (xx)
NZ (1) NZ520624A (xx)
PT (1) PT1274687E (xx)
WO (1) WO2001068609A1 (xx)
ZA (1) ZA200206467B (xx)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044172A1 (en) * 2000-11-28 2002-06-06 Smithkline Beecham P.L.C. Morpholine derivatives as antagonists of orexin receptors
GB0126292D0 (en) * 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
GB0130388D0 (en) * 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
ATE496884T1 (de) 2002-10-11 2011-02-15 Actelion Pharmaceuticals Ltd Sulphonylaminoessigsaeure derivate und deren verwendung als orexin rezeptor antagoniste
GB0225884D0 (en) * 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2006518757A (ja) * 2003-02-24 2006-08-17 メルク エンド カムパニー インコーポレーテッド ケモカイン受容体活性のアミノシクロペンチル縮合ヘテロ3環アミドモジュレーター
EP1611104B1 (en) * 2003-03-26 2009-07-01 Actelion Pharmaceuticals Ltd. Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
US7321065B2 (en) * 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
JP2007523846A (ja) 2003-04-28 2007-08-23 アクテリオン ファマシューティカルズ リミテッド キノキサリノン誘導体
US7547693B2 (en) 2003-09-22 2009-06-16 Banyu Pharmaceutical Co. Ltd. Piperidine derivative
US7459444B2 (en) * 2004-01-23 2008-12-02 Janssen Pharmaceutica N.V. Inhibitors of chymase
US20100048513A1 (en) 2008-08-20 2010-02-25 Hawkins Michael J Novel inhibitors of chymase
WO2005118548A1 (en) * 2004-03-01 2005-12-15 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
EP1814590B2 (en) 2004-11-01 2013-12-11 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
US20060178307A1 (en) * 2005-01-26 2006-08-10 The Regents Of The University Of California Modulation of NMDA receptor currents via orexin receptor and/or CRF receptor
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
US7501395B2 (en) 2005-04-25 2009-03-10 Eisai R & D Management Co., Ltd. Method of screening for antianxiety drugs
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CA2609388C (en) 2005-05-30 2013-08-06 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE
CN101277960A (zh) 2005-09-29 2008-10-01 默克公司 作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物
RU2008119687A (ru) 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений
US8163770B2 (en) 2005-10-27 2012-04-24 Msd. K. K. Benzoxathiin derivative
BRPI0618354B8 (pt) 2005-11-10 2021-05-25 Banyu Pharma Co Ltd composto e seu uso, composição farmacêutica, preventivo ou remédio
CN101374831B (zh) * 2006-01-26 2011-04-27 埃科特莱茵药品有限公司 四氢吡喃抗生素
EP1998774A1 (en) * 2006-03-15 2008-12-10 Actelion Pharmaceuticals Ltd. Tetrahydroisoquinoline derivatives to enhance memory function
ES2566481T3 (es) * 2006-04-12 2016-04-13 Merck Sharp & Dohme Corp. Antagonistas del canal de calcio de tipo T de piridil amida
JP2009535324A (ja) * 2006-04-26 2009-10-01 アクテリオン ファーマシューティカルズ リミテッド 新規なピラゾロ−テトラヒドロピリジン誘導体
JP2009543785A (ja) 2006-07-14 2009-12-10 メルク エンド カムパニー インコーポレーテッド 架橋ジアゼパンオレキシン受容体アンタゴニスト
CN101511833A (zh) * 2006-08-28 2009-08-19 埃科特莱茵药品有限公司 1,4,5,6,7,8-六氢-1,2,5-三氮杂-甘菊环烃衍生物
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008038692A1 (fr) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. dÉrivÉ de diarylcÉtimine
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CA2669561A1 (en) * 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
JP5319518B2 (ja) 2007-04-02 2013-10-16 Msd株式会社 インドールジオン誘導体
ES2365444T3 (es) * 2007-04-04 2011-10-05 F. Hoffmann-La Roche Ag Heterociclos como antagonistas de orexina.
WO2008143856A1 (en) 2007-05-18 2008-11-27 Merck & Co., Inc. Oxo bridged diazepan orexin receptor antagonists
CN101679366B (zh) 2007-05-23 2013-08-07 默沙东公司 吡啶基哌啶食欲素受体拮抗剂
JP2010528007A (ja) 2007-05-23 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション シクロプロピルピロリジンオレキシン受容体アンタゴニスト
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
PE20091010A1 (es) * 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
AU2008317353B2 (en) 2007-10-24 2014-08-07 Merck Sharp & Dohme Llc Heterocycle phenyl amide T-type calcium channel antagonists
JP5829399B2 (ja) 2007-12-28 2015-12-09 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd 3置換3,4−ジヒドロ−1h−イソキノリン化合物、その製造方法及びその使用
WO2009110510A1 (ja) 2008-03-06 2009-09-11 萬有製薬株式会社 アルキルアミノピリジン誘導体
WO2009119726A1 (ja) 2008-03-28 2009-10-01 萬有製薬株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
RU2010151951A (ru) 2008-05-20 2012-06-27 Ньюроджесэкс, Инк. (Us) Общие пролекарства гепатопротектора и ацетаминофена
WO2009154132A1 (ja) 2008-06-19 2009-12-23 萬有製薬株式会社 スピロジアミン-ジアリールケトオキシム誘導体
EP2307417A2 (en) * 2008-06-25 2011-04-13 Actelion Pharmaceuticals Ltd. 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2731358A1 (en) 2008-07-30 2010-02-04 Banyu Pharmaceutical Co., Ltd. 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
EP2161266A1 (en) 2008-08-22 2010-03-10 EVOTEC Neurosciences GmbH Benzofuran derivatives as orexin receptor antagonists
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010064212A1 (en) 2008-12-05 2010-06-10 Actelion Pharmaceuticals Ltd Method for obtaining an optically pure 1,2,3,4 tetrahydro-isoquinoline derivative
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2504316A1 (en) 2009-11-23 2012-10-03 MSD Oss B.V. Heterocylic compounds as antagonists of the orexin receptors
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
WO2011138266A1 (en) 2010-05-03 2011-11-10 Evotec Ag Indolizine and imidazopyridine derivatives as orexin receptor antagonists
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
EP2402322A1 (en) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8796258B2 (en) 2011-02-25 2014-08-05 Merck Sharp & Dohme Corp. Cyclic azabenzimidazole derivatives useful as anti-diabetic agents
DK2758060T3 (en) 2011-09-19 2018-03-05 Eth Zuerich ROR gamma modulators for the treatment of diabetes II complications
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014100719A2 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
CN104994848A (zh) 2013-02-22 2015-10-21 默沙东公司 抗糖尿病二环化合物
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2781217A1 (en) 2013-03-18 2014-09-24 ETH Zurich ROR gamma modulators
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
CN105198809A (zh) * 2015-09-24 2015-12-30 绍兴文理学院 一种2-(1-酰亚胺基甲基)-1,2,3,4-四氢异喹啉衍生物及其合成方法与应用
CN105418498A (zh) * 2015-12-30 2016-03-23 绍兴文理学院 一种1,2,3,4-四氢异喹啉衍生物及其合成方法与应用
WO2017194548A1 (en) 2016-05-10 2017-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
MX2019004321A (es) 2016-10-14 2019-06-12 Tes Pharma S R L Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
KR20210111248A (ko) 2018-11-20 2021-09-10 테스 파마 에스.알.엘. α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제
CN112538100B (zh) * 2020-12-16 2022-06-24 河南中医药大学 一种从黄柏中提取的具有抗炎活性的异喹啉生物碱苷类化合物及其制备方法与应用
KR102695633B1 (ko) * 2021-12-17 2024-08-14 한국화학연구원 피리미딘을 포함하는 테트라하이드로이소퀴놀린 유도체 및 이의 결핵 치료제 용도
TW202342433A (zh) * 2022-02-25 2023-11-01 比利時魯汶大學 用於抑制yap/taz—tead之二氫喹唑啉酮及相關類似物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE204917C (xx)
DE258817C (xx)
CA205079A (en) * 1920-10-26 Nelson Lionel Gas producer
DE261158C (xx)
CA110459A (en) * 1907-12-09 1908-02-25 Charles Albert Keller Electric furnace
CA173523A (en) * 1916-04-01 1916-11-28 Raymond B. Price Textile material
CA170679A (en) * 1916-05-26 1916-07-11 Edwin W. Webb Car brake
US3480714A (en) 1966-02-07 1969-11-25 Ciba Geigy Corp N-substituted isoquinolines as antiprotozoal agents
DD204917A1 (de) * 1981-12-31 1983-12-14 Gerhard Kempter Verfahren zur herstellung phenylsubstituierter und benzkondensierter cycloalkylaminoacetanilide
JPS6153268A (ja) 1984-08-24 1986-03-17 Hokuriku Seiyaku Co Ltd アントラニルアミド誘導体
DD261158A1 (de) * 1987-01-08 1988-10-19 Univ Halle Wittenberg Verfahren zur herstellung von 2-aminoalkyl-3,4-dihydro-4-oxo-7h-pyrrolo 2.3-d pyrimidinen
DD258817A1 (de) * 1987-01-19 1988-08-03 Univ Halle Wittenberg Verfahren zur herstellung von 2-(aminoalkyl) -pyrimido-4,5'-5,4 pyrrolo 3,2-f 1,4 thiazepinderivaten
AU652996B2 (en) 1991-01-11 1994-09-15 Laboratoires Glaxo S.A. Acridine derivatives
NZ268587A (en) * 1993-06-22 1998-01-26 Knoll Ag 1-cycloalkyl substituted tetrahydroisoquinoline derivatives and pharmaceutical compositions
JPH07267961A (ja) 1994-03-30 1995-10-17 Taisho Pharmaceut Co Ltd ベンゾフロ[3,2−dピリミジン−4−オン誘導体
JPH1095766A (ja) 1996-09-19 1998-04-14 Sanwa Kagaku Kenkyusho Co Ltd アセトアミド誘導体、及びその用途
WO1998023593A1 (en) * 1996-11-27 1998-06-04 Pfizer Inc. Apo b-secretion/mtp inhibitory amides
AR016817A1 (es) 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
US6372757B1 (en) * 1998-05-08 2002-04-16 Smithkline Beecham P.L.C. Phenylurea and phenylthio urea derivatives
WO2000029399A1 (en) * 1998-11-12 2000-05-25 Boehringer Ingelheim (Canada) Ltd. Antiherpes compounds
GB9827467D0 (en) 1998-12-15 1999-02-10 Zeneca Ltd Chemical compounds
GB9914015D0 (en) 1999-06-17 1999-08-18 Zeneca Ltd Chemical compounds
GB9914025D0 (en) 1999-06-17 1999-08-18 Zeneca Ltd Chemical compounds
WO2001002368A1 (en) 1999-07-06 2001-01-11 Vertex Pharmaceuticals Incorporated N-heterocyclic derivatives with neuronal activity

Also Published As

Publication number Publication date
NZ520624A (en) 2004-02-27
US20030176415A1 (en) 2003-09-18
BRPI0109200B8 (pt) 2021-05-25
HUP0300207A2 (en) 2003-05-28
IL150986A0 (en) 2003-02-12
KR20020080465A (ko) 2002-10-23
NO20024339L (no) 2002-09-11
IL150986A (en) 2007-07-04
HU227811B1 (en) 2012-03-28
MXPA02008797A (es) 2005-09-08
US6703392B2 (en) 2004-03-09
DE60108236T2 (de) 2005-12-22
BRPI0109200B1 (pt) 2015-08-11
ES2234840T3 (es) 2005-07-01
BR0109200A (pt) 2003-06-03
AU6011301A (en) 2001-09-24
NO20024339D0 (no) 2002-09-11
NO324932B1 (no) 2008-01-07
PT1274687E (pt) 2005-04-29
CN1416420A (zh) 2003-05-07
DE60108236D1 (de) 2005-02-10
WO2001068609B1 (en) 2002-02-21
KR100842698B1 (ko) 2008-07-01
KR20070087103A (ko) 2007-08-27
HUP0300207A3 (en) 2005-07-28
JP4009460B2 (ja) 2007-11-14
JP2003527374A (ja) 2003-09-16
AU2001260113B2 (en) 2006-04-06
WO2001068609A1 (en) 2001-09-20
CN100393703C (zh) 2008-06-11
ZA200206467B (en) 2003-11-13
CA2402431A1 (en) 2001-09-20
CA2402431C (en) 2009-10-06

Similar Documents

Publication Publication Date Title
ATE286500T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
NO20051102L (no) Sulfonylamino-eddiksyre-derivater
IL155806A0 (en) Novel benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
MXPA03004780A (es) Nuevas sulfamidas.
NO20034230L (no) 1,2,3,4-tetrahydroisokinolin-derivater som urotensin II reseptor-antagonister
MXPA05010137A (es) Derivados de tetrahidroisoquinolil acetamida para usarse como antagonistas del receptor de orexina.
NO20042844L (no) 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister
ATE383345T1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
MXPA04001252A (es) Nuevos heterociclos benzo-fusionados como antagonistas de endotelina.
IL168836A (en) Pyrimidine-sulfamides and their use as endothelin receptor antagonist
WO2002024665A8 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
MXPA03000430A (es) Nuevas arileteno-sulfonamidas.
MXPA03000606A (es) Derivados de benzofurano y su uso como agentes antibacterianos.
MXPA04001773A (es) Derivados de 6,7-dihidroxitetrahidroisquinolinas 3-sustituidas parta uso como agentes antibacterianos.
MXPA02006250A (es) Derivados de butino diol.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1274687

Country of ref document: EP